The purpose of this new, reorganized Core is to provide physics, optical imaging and spectroscopy, and mathematical modeling support for the PPG. In so doing, we anticipate that new methods and approaches will be developed in close connection to the specific aims of the 5 individual projects. Optics is of course a critical element of PDT, and optical dosimetry has been a theme of the Core from the beginning. The new scientific emphasis of the Core builds on the realization that there are significant opportunities to exploit advances in biomedical optics within the context of preclinical and clinical PDT. Because of its long tradition of bringing PDT from the laboratory to the clinic, Roswell Park Cancer Institute (RPCI) is perhaps uniquely situated in the United States to make breakthroughs in this area. Exciting opportunities exist on several levels. For example, the lesions treated by PDT are necessarily optically accessible, and this enables integration of optical spectroscopic monitoring with the delivery of PDT. The photosensitizers used in PDT fluoresce, and this renders them directly detectable via fluorescence imaging in cells and in vivo. Advances in molecular imaging strategies have made it possible to image therapy-induced gene expression, tumor and normal tissue vasculature, and host cell responses to treatment in vivo at subcellular resolution. Important advances in understanding the various factors that contribute to the microscopic deposition of photodynamic dose have led to the development of new and very powerful mathematical models of PDT dosimetry, which have the capability of informing and being informed by ongoing and planned clinical trials. An additional important role for the Core is to continue to provide outstanding technical support for the preclinical and clinical laser and fiber delivery systems that are integral to each of the projects.
The specific aims of the Optical Spectroscopy, Molecular Imaging, and Dosimetry Modeling Core are: 1) To continue to provide technical and scientific support for the clinical instrument that integrates PDT delivery with fluorescence and reflectance spectroscopy;2) To develop in vivo molecular imaging methods in close connection to all projects;3) To utilize a new model of microscopic PDT dosimetry to inform the design and interpretation of clinical trials;and 4) To provide routine engineering and optics support for the clinical and preclinical research efforts of the PPG.

Public Health Relevance

Photodynamic therapy (PDT) is an emerging treatment already approved by the US FDA for several cancers and pre-cancers. The Program Project studies means of further optimizing this therapy by developing new photosensitizing drugs, exploring the mechanisms by which the therapy eradicates tumors, and by pursuing important new clinical trials. This Core provides critical optics support to the 5 projects of the Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055791-20
Application #
8462219
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
2015-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
20
Fiscal Year
2013
Total Cost
$180,629
Indirect Cost
$72,636
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75
Shafirstein, Gal; Rigual, Nestor R; Arshad, Hassan et al. (2016) Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study. Head Neck 38 Suppl 1:E377-83
James, Nadine S; Joshi, Penny; Ohulchanskyy, Tymish Y et al. (2016) Photosensitizer (PS)-cyanine dye (CD) conjugates: Impact of the linkers joining the PS and CD moieties and their orientation in tumor-uptake and photodynamic therapy (PDT). Eur J Med Chem 122:770-85
Brackett, Craig M; Kojouharov, Bojidar; Veith, Jean et al. (2016) Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci U S A 113:E874-83
Dhillon, Samjot Singh; Demmy, Todd L; Yendamuri, Sai et al. (2016) A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study. J Thorac Oncol 11:234-41
Rohrbach, Daniel J; Rigual, Nestor; Arshad, Hassan et al. (2016) Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma. J Biomed Opt 21:18002
Jenkins, Samir V; Srivatsan, Avinash; Reynolds, Kimberly Y et al. (2016) Understanding the interactions between porphyrin-containing photosensitizers and polymer-coated nanoparticles in model biological environments. J Colloid Interface Sci 461:225-31
Patel, Nayan J; Chen, Yihui; Joshi, Penny et al. (2016) Effect of Metalation on Porphyrin-Based Bifunctional Agents in Tumor Imaging and Photodynamic Therapy. Bioconjug Chem 27:667-80
Baran, Timothy M (2016) Recovery of optical properties using interstitial cylindrical diffusers as source and detector fibers. J Biomed Opt 21:77001
Ito, Fumito; Ku, Amy W; Bucsek, Mark J et al. (2015) Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. PLoS One 10:e0143370

Showing the most recent 10 out of 157 publications